EMJ GOLD
@emjgold.bsky.social
The latest pharma news, views and analysis.
Sign up to our mailing list to receive insights direct to your inbox: https://emjreviews.com/mailing-list/
Sign up to our mailing list to receive insights direct to your inbox: https://emjreviews.com/mailing-list/
How is one pharma company helping to bring athletes back from injury and become gold medal winners?
Eli Lilly has partnered with the USOPC on the Team USA Athlete Recovery Scheme, supporting athletes from MilanoCortina2026 to LA28.
Find out more: www.emjreviews.com/emj-gold/new...
Eli Lilly has partnered with the USOPC on the Team USA Athlete Recovery Scheme, supporting athletes from MilanoCortina2026 to LA28.
Find out more: www.emjreviews.com/emj-gold/new...
Eli Lilly and USOPC launch athlete recovery programme
The initiative aims to provide elite athletes with targeted rehabilitation and holistic care for complex or extended recovery needs.
www.emjreviews.com
February 17, 2026 at 4:07 PM
How is one pharma company helping to bring athletes back from injury and become gold medal winners?
Eli Lilly has partnered with the USOPC on the Team USA Athlete Recovery Scheme, supporting athletes from MilanoCortina2026 to LA28.
Find out more: www.emjreviews.com/emj-gold/new...
Eli Lilly has partnered with the USOPC on the Team USA Athlete Recovery Scheme, supporting athletes from MilanoCortina2026 to LA28.
Find out more: www.emjreviews.com/emj-gold/new...
Did you know only 10% of R&D programmes result in an approved medicine?
A new ABPI review explores how the UK can close this gap by making advanced academic lab and AI models industry-ready.
Learn more: www.emjreviews.com/emj-gold/new...
A new ABPI review explores how the UK can close this gap by making advanced academic lab and AI models industry-ready.
Learn more: www.emjreviews.com/emj-gold/new...
ABPI launch report to bridge UK’s drug discovery gap
As it stands, the pharmaceutical industry faces a significant technical bottleneck: only 10% of R&D ends in an approved medicine.
www.emjreviews.com
February 13, 2026 at 4:46 PM
Did you know only 10% of R&D programmes result in an approved medicine?
A new ABPI review explores how the UK can close this gap by making advanced academic lab and AI models industry-ready.
Learn more: www.emjreviews.com/emj-gold/new...
A new ABPI review explores how the UK can close this gap by making advanced academic lab and AI models industry-ready.
Learn more: www.emjreviews.com/emj-gold/new...
Sanofi names Belén Garijo as new CEO 🧪
The Merck KGaA veteran, who previously had a 15-year career at Sanofi, is returning to the group on a mission to accelerate innovation and strengthen governance.
Read more on the latest pharma leadership shift: www.emjreviews.com/emj-gold/new...
The Merck KGaA veteran, who previously had a 15-year career at Sanofi, is returning to the group on a mission to accelerate innovation and strengthen governance.
Read more on the latest pharma leadership shift: www.emjreviews.com/emj-gold/new...
Sanofi names Belén Garijo as CEO to lead R&D growth
Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of Paul Hudson.
www.emjreviews.com
February 12, 2026 at 10:40 AM
Sanofi names Belén Garijo as new CEO 🧪
The Merck KGaA veteran, who previously had a 15-year career at Sanofi, is returning to the group on a mission to accelerate innovation and strengthen governance.
Read more on the latest pharma leadership shift: www.emjreviews.com/emj-gold/new...
The Merck KGaA veteran, who previously had a 15-year career at Sanofi, is returning to the group on a mission to accelerate innovation and strengthen governance.
Read more on the latest pharma leadership shift: www.emjreviews.com/emj-gold/new...
Is rare disease care access in the US a "zip code lottery"?
NORD's 2025 State Report Card reveals that state-level legislation is now the primary driver for orphan drug access.
Learn more: www.emjreviews.com/emj-gold/new...
NORD's 2025 State Report Card reveals that state-level legislation is now the primary driver for orphan drug access.
Learn more: www.emjreviews.com/emj-gold/new...
Rare disease access remains uneven across the US
A new report has found that for Americans living with rare conditions, access to the latest innovations can depend on their zip code.
www.emjreviews.com
February 11, 2026 at 10:56 AM
Is rare disease care access in the US a "zip code lottery"?
NORD's 2025 State Report Card reveals that state-level legislation is now the primary driver for orphan drug access.
Learn more: www.emjreviews.com/emj-gold/new...
NORD's 2025 State Report Card reveals that state-level legislation is now the primary driver for orphan drug access.
Learn more: www.emjreviews.com/emj-gold/new...
Is Europe ready for the ePI transition?
A new report explores electronic Product Information (ePI) pilot programmes across 31 European countries, offering fresh insight into how digital leaflets could replace traditional paper versions.
Learn more: www.emjreviews.com/emj-gold/new...
A new report explores electronic Product Information (ePI) pilot programmes across 31 European countries, offering fresh insight into how digital leaflets could replace traditional paper versions.
Learn more: www.emjreviews.com/emj-gold/new...
Momentum grows for Europe’s ePI transition
A landmark European report offers a comprehensive analysis of electronic Product Information (ePI) pilot projects across 31 countries.
www.emjreviews.com
February 10, 2026 at 9:43 AM
Is Europe ready for the ePI transition?
A new report explores electronic Product Information (ePI) pilot programmes across 31 European countries, offering fresh insight into how digital leaflets could replace traditional paper versions.
Learn more: www.emjreviews.com/emj-gold/new...
A new report explores electronic Product Information (ePI) pilot programmes across 31 European countries, offering fresh insight into how digital leaflets could replace traditional paper versions.
Learn more: www.emjreviews.com/emj-gold/new...
India has launched Biopharma SHAKTI, a $1.1bn initiative to pivot the country from a generics to a high-value biologics leader and targets a 5% share of the $1.1tn global pharmaceutical market.
Read the full story: www.emjreviews.com/emj-gold/new...
Read the full story: www.emjreviews.com/emj-gold/new...
February 6, 2026 at 10:49 AM
India has launched Biopharma SHAKTI, a $1.1bn initiative to pivot the country from a generics to a high-value biologics leader and targets a 5% share of the $1.1tn global pharmaceutical market.
Read the full story: www.emjreviews.com/emj-gold/new...
Read the full story: www.emjreviews.com/emj-gold/new...
Month in pharma: January 2026, explained 👇
From updated flu vaccine warnings driven by RWE, to a $15bn investment shift signalling China’s growing pull on global R&D, January highlighted how there is never a dull day in life sciences.
Read the round up: www.emjreviews.com/emj-gold/new...
From updated flu vaccine warnings driven by RWE, to a $15bn investment shift signalling China’s growing pull on global R&D, January highlighted how there is never a dull day in life sciences.
Read the round up: www.emjreviews.com/emj-gold/new...
Month in pharma news, explained – January 2026
In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on January 2026.
www.emjreviews.com
February 5, 2026 at 11:50 AM
Month in pharma: January 2026, explained 👇
From updated flu vaccine warnings driven by RWE, to a $15bn investment shift signalling China’s growing pull on global R&D, January highlighted how there is never a dull day in life sciences.
Read the round up: www.emjreviews.com/emj-gold/new...
From updated flu vaccine warnings driven by RWE, to a $15bn investment shift signalling China’s growing pull on global R&D, January highlighted how there is never a dull day in life sciences.
Read the round up: www.emjreviews.com/emj-gold/new...
The UK and Japan strengthen R&D ties with an £11m investment in gene therapy manufacturing and a national rare disease genomics pilot. The partnership leverages AI and quantum computing to accelerate drug discovery.
Learn more on the collaboration: www.emjreviews.com/emj-gold/new...
Learn more on the collaboration: www.emjreviews.com/emj-gold/new...
UK and Japan strengthen science and technology ties
The UK and Japan have announced a sweeping pharmaceutical and technology partnership aimed at accelerating drug discovery.
www.emjreviews.com
February 4, 2026 at 3:54 PM
The UK and Japan strengthen R&D ties with an £11m investment in gene therapy manufacturing and a national rare disease genomics pilot. The partnership leverages AI and quantum computing to accelerate drug discovery.
Learn more on the collaboration: www.emjreviews.com/emj-gold/new...
Learn more on the collaboration: www.emjreviews.com/emj-gold/new...
Nipah in West Bengal: A Call for Pharma Readiness
Recent Nipah virus (NiV) cases in West Bengal underscore the urgent need for licensed countermeasures. With a 75% fatality rate, the industry is moving toward proactive intervention.
Learn more here: www.emjreviews.com/emj-gold/new...
Recent Nipah virus (NiV) cases in West Bengal underscore the urgent need for licensed countermeasures. With a 75% fatality rate, the industry is moving toward proactive intervention.
Learn more here: www.emjreviews.com/emj-gold/new...
Nipah in West Bengal: a pharma call to action
With two new Nipah virus cases confirmed, the pressure is mounting on the pharmaceutical industry to manufacture a vaccine.
www.emjreviews.com
February 3, 2026 at 11:29 AM
Nipah in West Bengal: A Call for Pharma Readiness
Recent Nipah virus (NiV) cases in West Bengal underscore the urgent need for licensed countermeasures. With a 75% fatality rate, the industry is moving toward proactive intervention.
Learn more here: www.emjreviews.com/emj-gold/new...
Recent Nipah virus (NiV) cases in West Bengal underscore the urgent need for licensed countermeasures. With a 75% fatality rate, the industry is moving toward proactive intervention.
Learn more here: www.emjreviews.com/emj-gold/new...
Newsflash: AstraZeneca makes a multi-billion dollar investment in China.
CEO Pascal Soriot called it “an exciting next chapter” for the company. The announcement came during UK PM Keir Starmer’s visit, who highlighted the benefits for the UK.
Full story: www.emjreviews.com/emj-gold/new...
CEO Pascal Soriot called it “an exciting next chapter” for the company. The announcement came during UK PM Keir Starmer’s visit, who highlighted the benefits for the UK.
Full story: www.emjreviews.com/emj-gold/new...
AstraZeneca bets big on China with $15bn investment
Pascal Soriot, CEO, AZ, hailed the investment as the start of "an exciting next chapter" for the company in China.
www.emjreviews.com
January 30, 2026 at 1:43 PM
Newsflash: AstraZeneca makes a multi-billion dollar investment in China.
CEO Pascal Soriot called it “an exciting next chapter” for the company. The announcement came during UK PM Keir Starmer’s visit, who highlighted the benefits for the UK.
Full story: www.emjreviews.com/emj-gold/new...
CEO Pascal Soriot called it “an exciting next chapter” for the company. The announcement came during UK PM Keir Starmer’s visit, who highlighted the benefits for the UK.
Full story: www.emjreviews.com/emj-gold/new...
Could this open doors for pharma?
A new briefing from the @oigdc.bsky.social sheds light on how pharma can offer lower costs directly to patients while staying clear of anti-kickback pitfalls.
Learn more about the guidelines: hubs.la/Q040W8mQ0
A new briefing from the @oigdc.bsky.social sheds light on how pharma can offer lower costs directly to patients while staying clear of anti-kickback pitfalls.
Learn more about the guidelines: hubs.la/Q040W8mQ0
TrumpRx: Guidance on DTC sales issued to industry
The Office of Inspector General's bulletin provides a framework for pharma companies selling prescription drugs direct-to-consumers (DTC).
hubs.la
January 29, 2026 at 5:14 PM
Could this open doors for pharma?
A new briefing from the @oigdc.bsky.social sheds light on how pharma can offer lower costs directly to patients while staying clear of anti-kickback pitfalls.
Learn more about the guidelines: hubs.la/Q040W8mQ0
A new briefing from the @oigdc.bsky.social sheds light on how pharma can offer lower costs directly to patients while staying clear of anti-kickback pitfalls.
Learn more about the guidelines: hubs.la/Q040W8mQ0
US government names 15 drugs for the 3rd round of Medicare price negotiations.
This selection is a watershed moment for industry as it moves beyond retail pharmacy and into physician-prescribed treatments.
Learn what therapy areas are on the list: www.emjreviews.com/emj-gold/new...
This selection is a watershed moment for industry as it moves beyond retail pharmacy and into physician-prescribed treatments.
Learn what therapy areas are on the list: www.emjreviews.com/emj-gold/new...
US government negotiates Medicare part B drugs
The CMS has unveiled the 15 high-cost medications selected for the next phase of the Medicare Drug Price Negotiation Program.
www.emjreviews.com
January 28, 2026 at 3:18 PM
US government names 15 drugs for the 3rd round of Medicare price negotiations.
This selection is a watershed moment for industry as it moves beyond retail pharmacy and into physician-prescribed treatments.
Learn what therapy areas are on the list: www.emjreviews.com/emj-gold/new...
This selection is a watershed moment for industry as it moves beyond retail pharmacy and into physician-prescribed treatments.
Learn what therapy areas are on the list: www.emjreviews.com/emj-gold/new...
A new survey by @sapiosciences.bsky.social of 150 researchers shows that outdated digital tools are driving a surge in shadow AI, which is the use of unauthorised AI tools in pharma and biotech labs.
Is it time to rethink lab digitalisation?
Full report: www.emjreviews.com/emj-gold/new...
Is it time to rethink lab digitalisation?
Full report: www.emjreviews.com/emj-gold/new...
When ELNs fall short: why R&D is turning to AI
A new study shows how limitations in electronic lab notebooks (ELNs) are driving pharma R&D teams to use AI tools, raising privacy concerns.
www.emjreviews.com
January 28, 2026 at 9:28 AM
A new survey by @sapiosciences.bsky.social of 150 researchers shows that outdated digital tools are driving a surge in shadow AI, which is the use of unauthorised AI tools in pharma and biotech labs.
Is it time to rethink lab digitalisation?
Full report: www.emjreviews.com/emj-gold/new...
Is it time to rethink lab digitalisation?
Full report: www.emjreviews.com/emj-gold/new...
Are more young adults turning to AI for sensitive health concerns?
A survey of 2,520 US adults aged 18–29 found that one in five have asked an AI chatbot about STIs, while one in 10 used AI to help identify a possible infection.
Discover more: www.emjreviews.com/emj-gold/new...
A survey of 2,520 US adults aged 18–29 found that one in five have asked an AI chatbot about STIs, while one in 10 used AI to help identify a possible infection.
Discover more: www.emjreviews.com/emj-gold/new...
Gen Z increasingly turning to AI for STI advice
A growing number of Gen Z are turning to AI chatbots for sexual health advice, including the diagnosis of sexually transmitted infections.
www.emjreviews.com
January 26, 2026 at 4:58 PM
Are more young adults turning to AI for sensitive health concerns?
A survey of 2,520 US adults aged 18–29 found that one in five have asked an AI chatbot about STIs, while one in 10 used AI to help identify a possible infection.
Discover more: www.emjreviews.com/emj-gold/new...
A survey of 2,520 US adults aged 18–29 found that one in five have asked an AI chatbot about STIs, while one in 10 used AI to help identify a possible infection.
Discover more: www.emjreviews.com/emj-gold/new...
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have launched Gr-ADI, a $60m consortium designed to bridge the market gap in antibiotic discovery.
Explore more: www.emjreviews.com/emj-gold/new...
Explore more: www.emjreviews.com/emj-gold/new...
Major philanthropies launch $60m AMR consortium
This first-of-its-kind global consortium aims to accelerate the discovery of treatments for the world’s most resistant pathogens.
www.emjreviews.com
January 22, 2026 at 5:09 PM
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have launched Gr-ADI, a $60m consortium designed to bridge the market gap in antibiotic discovery.
Explore more: www.emjreviews.com/emj-gold/new...
Explore more: www.emjreviews.com/emj-gold/new...
Paracetamol safety profile reaffirmed?
A study has found no link between prenatal paracetamol use and neurodevelopmental risks. For industry stakeholders, this is a critical defence of a cornerstone analgesic.
Read the latest: www.emjreviews.com/emj-gold/new...
A study has found no link between prenatal paracetamol use and neurodevelopmental risks. For industry stakeholders, this is a critical defence of a cornerstone analgesic.
Read the latest: www.emjreviews.com/emj-gold/new...
Paracetamol safety: New study finds no autism link
A review has provided evidence debunking claims that acetaminophen (paracetamol) use during pregnancy increases the risk of ASD and ADHD.
www.emjreviews.com
January 20, 2026 at 4:58 PM
Paracetamol safety profile reaffirmed?
A study has found no link between prenatal paracetamol use and neurodevelopmental risks. For industry stakeholders, this is a critical defence of a cornerstone analgesic.
Read the latest: www.emjreviews.com/emj-gold/new...
A study has found no link between prenatal paracetamol use and neurodevelopmental risks. For industry stakeholders, this is a critical defence of a cornerstone analgesic.
Read the latest: www.emjreviews.com/emj-gold/new...
The FDA is leveraging real-world evidence (RWE) to update flu vaccine labels. 💉
Following a BEST study, specific manufacturers must now note a small risk of febrile seizures in young children within 24 hours of vaccination.
Details here: www.emjreviews.com/emj-gold/new...
Following a BEST study, specific manufacturers must now note a small risk of febrile seizures in young children within 24 hours of vaccination.
Details here: www.emjreviews.com/emj-gold/new...
FDA orders seizure warnings for major flu vaccines
The FDA has directed pharma companies of influenza vaccines to update their product labelling to include the risk of fever-induced seizures.
www.emjreviews.com
January 19, 2026 at 4:11 PM
The FDA is leveraging real-world evidence (RWE) to update flu vaccine labels. 💉
Following a BEST study, specific manufacturers must now note a small risk of febrile seizures in young children within 24 hours of vaccination.
Details here: www.emjreviews.com/emj-gold/new...
Following a BEST study, specific manufacturers must now note a small risk of febrile seizures in young children within 24 hours of vaccination.
Details here: www.emjreviews.com/emj-gold/new...
$1bn. 5 years. One goal: Reinvent the R&D lifecycle 💻
Eli Lilly and NVIDIA are launching a first-of-its-kind AI co-innovation lab to solve some of the industry’s toughest bottlenecks.
Read more: www.emjreviews.com/emj-gold/new...
Eli Lilly and NVIDIA are launching a first-of-its-kind AI co-innovation lab to solve some of the industry’s toughest bottlenecks.
Read more: www.emjreviews.com/emj-gold/new...
Lilly and NVIDIA: a $1bn leap for drug discovery
Eli Lilly and NVIDIA have unveiled a first-of-its-kind AI co-innovation lab, aiming to solving the most complex bottlenecks in pharma.
www.emjreviews.com
January 13, 2026 at 3:38 PM
$1bn. 5 years. One goal: Reinvent the R&D lifecycle 💻
Eli Lilly and NVIDIA are launching a first-of-its-kind AI co-innovation lab to solve some of the industry’s toughest bottlenecks.
Read more: www.emjreviews.com/emj-gold/new...
Eli Lilly and NVIDIA are launching a first-of-its-kind AI co-innovation lab to solve some of the industry’s toughest bottlenecks.
Read more: www.emjreviews.com/emj-gold/new...
Pharma urges the FDA to modernise cell and gene therapy tracking, adopting Federated Data Networks and ICH M14 standards to automate data collection and reduce clinic burden. 🧬
Read more: www.emjreviews.com/emj-gold/new...
Read more: www.emjreviews.com/emj-gold/new...
Pharma to FDA: Upgrade cell and gene data sharing
The pharmaceutical industry is calling on the FDA to modernise how it tracks the long-term safety and efficacy of cell and gene therapies.
www.emjreviews.com
January 12, 2026 at 5:02 PM
Pharma urges the FDA to modernise cell and gene therapy tracking, adopting Federated Data Networks and ICH M14 standards to automate data collection and reduce clinic burden. 🧬
Read more: www.emjreviews.com/emj-gold/new...
Read more: www.emjreviews.com/emj-gold/new...
Can we bypass cancer resistance?
With the $3.05bn acquisition of Halda, J&J gains the "hold and kill" RIPTAC platform – a novel weapon against treatment-resistant tumors.
"Designed to work even when cancers no longer respond." – Prof John Reed, J&J.
Read more: www.emjreviews.com/en-us/amj/em...
With the $3.05bn acquisition of Halda, J&J gains the "hold and kill" RIPTAC platform – a novel weapon against treatment-resistant tumors.
"Designed to work even when cancers no longer respond." – Prof John Reed, J&J.
Read more: www.emjreviews.com/en-us/amj/em...
End of lifelong pills? GSK’s phase 3 success in hepatitis B
GSK announced in January that its novel chronic hepatitis B successfully met primary goals in two pivotal phase 3 trials.
www.emjreviews.com
January 9, 2026 at 4:25 PM
Can we bypass cancer resistance?
With the $3.05bn acquisition of Halda, J&J gains the "hold and kill" RIPTAC platform – a novel weapon against treatment-resistant tumors.
"Designed to work even when cancers no longer respond." – Prof John Reed, J&J.
Read more: www.emjreviews.com/en-us/amj/em...
With the $3.05bn acquisition of Halda, J&J gains the "hold and kill" RIPTAC platform – a novel weapon against treatment-resistant tumors.
"Designed to work even when cancers no longer respond." – Prof John Reed, J&J.
Read more: www.emjreviews.com/en-us/amj/em...
In a landmark shift, the CDC has formally reduced its routine childhood vaccine recommendations from 17 down to 11.
The move marks a transition from decades of universal mandates towards shared clinical decision making.
Find out more on EMJ GOLD: www.emjreviews.com/emj-gold/new...
The move marks a transition from decades of universal mandates towards shared clinical decision making.
Find out more on EMJ GOLD: www.emjreviews.com/emj-gold/new...
US slashes vaccine schedule: a major shift for paediatrics
CDC has formally reduced its routine childhood vaccine recommendations from 17 to 11, marking a major shift in US healthcare, read more.
www.emjreviews.com
January 9, 2026 at 10:46 AM
In a landmark shift, the CDC has formally reduced its routine childhood vaccine recommendations from 17 down to 11.
The move marks a transition from decades of universal mandates towards shared clinical decision making.
Find out more on EMJ GOLD: www.emjreviews.com/emj-gold/new...
The move marks a transition from decades of universal mandates towards shared clinical decision making.
Find out more on EMJ GOLD: www.emjreviews.com/emj-gold/new...
Pharma Year in Review 2025 🌍
2025 was a year of incredible healthcare momentum balanced by regulatory challenges.
Join Hanna Svanbäck, Jonathan Sackier, and Yacin Marzouki as they reflect on 2025.
🎧 Listen here: www.emjreviews.com/emj-gold/pod...
2025 was a year of incredible healthcare momentum balanced by regulatory challenges.
Join Hanna Svanbäck, Jonathan Sackier, and Yacin Marzouki as they reflect on 2025.
🎧 Listen here: www.emjreviews.com/emj-gold/pod...
January 7, 2026 at 2:55 PM
Pharma Year in Review 2025 🌍
2025 was a year of incredible healthcare momentum balanced by regulatory challenges.
Join Hanna Svanbäck, Jonathan Sackier, and Yacin Marzouki as they reflect on 2025.
🎧 Listen here: www.emjreviews.com/emj-gold/pod...
2025 was a year of incredible healthcare momentum balanced by regulatory challenges.
Join Hanna Svanbäck, Jonathan Sackier, and Yacin Marzouki as they reflect on 2025.
🎧 Listen here: www.emjreviews.com/emj-gold/pod...
Welcome to Unwrapped! 🎄
We’re wrapping up 2025 with a special content series, reflecting on the past year in pharma. First up, try our tricky brain teaser challenge. What could it be?
🎁 Reveal the answer and explore more here: www.emjreviews.com/emj-gold/art...
We’re wrapping up 2025 with a special content series, reflecting on the past year in pharma. First up, try our tricky brain teaser challenge. What could it be?
🎁 Reveal the answer and explore more here: www.emjreviews.com/emj-gold/art...
December 16, 2025 at 5:17 PM
Welcome to Unwrapped! 🎄
We’re wrapping up 2025 with a special content series, reflecting on the past year in pharma. First up, try our tricky brain teaser challenge. What could it be?
🎁 Reveal the answer and explore more here: www.emjreviews.com/emj-gold/art...
We’re wrapping up 2025 with a special content series, reflecting on the past year in pharma. First up, try our tricky brain teaser challenge. What could it be?
🎁 Reveal the answer and explore more here: www.emjreviews.com/emj-gold/art...
A new leader for a new era?
Prof Jonathan's Benger's appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
Learn more: www.emjreviews.com/emj-gold/new...
Prof Jonathan's Benger's appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
Learn more: www.emjreviews.com/emj-gold/new...
NICE appoints Prof Jonathan Benger as new CEO
His appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
www.emjreviews.com
December 16, 2025 at 1:55 PM
A new leader for a new era?
Prof Jonathan's Benger's appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
Learn more: www.emjreviews.com/emj-gold/new...
Prof Jonathan's Benger's appointment comes at a pivotal moment for the organisation, as NICE prepares to help deliver the 10 Year Health Plan for the NHS.
Learn more: www.emjreviews.com/emj-gold/new...
In our latest Catalyst interview, medical affairs leader Dr Michael Zaiac, Daiichi Sankyo, discusses personalised medicine adoption, including the significant role that biomarkers and AI will play in the future of oncology.
Watch the full interview: www.emjreviews.com/emj-gold/art...
Watch the full interview: www.emjreviews.com/emj-gold/art...
December 10, 2025 at 3:07 PM
In our latest Catalyst interview, medical affairs leader Dr Michael Zaiac, Daiichi Sankyo, discusses personalised medicine adoption, including the significant role that biomarkers and AI will play in the future of oncology.
Watch the full interview: www.emjreviews.com/emj-gold/art...
Watch the full interview: www.emjreviews.com/emj-gold/art...